Kamada (KMDA) Downgraded to Strong Sell at ValuEngine
Kamada (NASDAQ:KMDA) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Thursday.
KMDA has been the topic of several other research reports. TheStreet raised shares of Kamada from a “c” rating to a “b” rating in a research report on Friday, February 9th. Zacks Investment Research raised shares of Kamada from a “sell” rating to a “hold” rating in a research report on Friday, February 9th. HC Wainwright reissued a “buy” rating on shares of Kamada in a research report on Thursday, February 8th. Finally, Chardan Capital started coverage on shares of Kamada in a research report on Friday, February 2nd. They set a “buy” rating and a $7.00 target price on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Kamada currently has an average rating of “Hold” and a consensus price target of $7.00.
NASDAQ:KMDA opened at $5.00 on Thursday. The company has a market cap of $191.25 million, a price-to-earnings ratio of 27.78 and a beta of 1.17. Kamada has a twelve month low of $4.65 and a twelve month high of $4.85. The company has a current ratio of 3.30, a quick ratio of 2.58 and a debt-to-equity ratio of 0.02.
A hedge fund recently bought a new stake in Kamada stock. ARK Investment Management LLC acquired a new stake in Kamada Ltd. (NASDAQ:KMDA) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 52,695 shares of the biotechnology company’s stock, valued at approximately $251,000. ARK Investment Management LLC owned about 0.13% of Kamada at the end of the most recent reporting period. 9.42% of the stock is owned by institutional investors.
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.